Clinical Trial

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase I trial studies the side effects of nivolumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Protocol Amendment History 39 amendments
This ClinicalTrials.gov record has been amended 39 times since 2020-03-24; most recent amendment 2026-06-11.
Status change: Recruiting → Active, Not Recruiting 2026-06-11
Status change: Active, Not Recruiting → Recruiting 2023-12-13
Status change: Recruiting → Active, Not Recruiting 2022-10-14
Status change: Not Yet Recruiting → Recruiting 2020-10-05
Trial Details
NCT Number NCT04323046
Lead Sponsor Sabine Mueller, MD, PhD
Collaborators: Pediatric Neuro-Oncology Consortium
Conditions Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Grade III Glioma, Grade III Glioma
Enrollment 9 participants
Start Date 2020-10-02
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-15